2026-01-19 - Analysis Report
**English Stock Report for Eli Lilly (LLY)**
============================================

### Company Overview
Eli Lilly - 당뇨, 비만 치료제 등 혁신 신약 제약사

### 1. Cumulative Return Comparison

* Cumulative return of review stock (LLY): 117.14%
* Cumulative return of comparison stock (S&P 500, VOO): 82.54%
* Divergence (current): N/A
* Relative divergence: N/A (will be calculated based on fluctuation range)

### 2. Stock Price Fluctuations

* Close: $1,038.40
* Last-market: 
 * PreviousClose: $1032.97
 * Change: 0.53
* 5-day SMA: $1,060.57
* 20-day SMA: $1,070.50
* 60-day SMA: $1,009.06

### 3. RSI, PPO, and Delta_Previous_Relative_Divergence Analysis

* Market Risk Indicator (MRI): 0.80 (High Investment Recommended)
* RSI: 41.58
* PPO: -0.70
* Hybrid Signal: Sell (Shares 78%)
* Recent (20 days) relative divergence change: 0.0 (flat)
* 7-day Rank change: 0 (flat)
* 7-day Dynamic Expected Return change: 0.0 (flat)
* Expected Return (%): N/A

### 4. News & Significant Events
- Recent news articles show that Eli Lilly stock has been impacted by delays in FDA decisions regarding new drugs, including a recent weight-loss pill.

### 5. Analyst Opinions

* Analyst Consensus:
 * Key: Buy
 * Mean (1=StrongBuy~5=Sell): 1.70 (~Buy)
 * Opinions: 28
 * Target Price (avg/high/low): 1110.79 / 1500.00 / 770.00

### 6. Recent Earnings Analysis
| Date | EPS | Revenue |
|---|---:|---:|
| 2025-10-30 | 6.22 | 17.60 B$ |
| 2025-08-07 | 6.3 | 15.56 B$ |
| 2025-05-01 | 3.07 | 12.73 B$ |
| 2024-10-30 | 1.08 | 11.44 B$ |
| 2025-10-30 | 1.08 | 11.44 B$ |

### 7. Financial Information - Revenue and Profitability

| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2025-09-30 | $17.60B | 82.91% |
| 2025-06-30 | $15.56B | 84.27% |
| 2025-03-31 | $12.73B | 82.53% |
| 2024-12-31 | $13.53B | 82.24% |
| 2024-09-30 | $11.44B | 81.02% |

### 7. Financial Information - Capital and Profitability

| Quarter | Equity | ROE |
|---------|---------|-----|
| 2025-09-30 | $23.79B | 23.46% |
| 2025-06-30 | $18.27B | 30.98% |
| 2025-03-31 | $15.76B | 17.50% |
| 2024-12-31 | $14.19B | 31.07% |
| 2024-09-30 | $14.24B | 6.81% |

**Comprehensive Analysis (Summary of previous items)**
-----------------------------------------------------

The comprehensive analysis combines the results from each section:

* Cumulative return comparison highlights that Eli Lilly stock has experienced significant growth, exceeding the S&P 500, VOO return.
* Stock price fluctuations indicate that prices have recovered from their recent downturn, suggesting a potential upward trend.
* RSI, PPO, and other metric analysis show that the short-term trend seems bearish, but the long-term outlook seems more positive.
* Recent news articles indicate that potential delays in FDA decisions may impact the stock price.
* Analyst opinions remain generally positive, with a mean rating of 1.70 (~Buy).
* Recent earnings analysis shows consistent EPS growth, with an 8.5% increase in the last quarter of 2025.
* Financial information reveals strong revenue growth and increasing profitability.

Please consider these concrete headlines/links in your analysis.
Eli Lilly (LLY) stock's recent fluctuation may be due to the reported delay in FDA decision for the weight loss pill.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.